Ligand Pharmaceuticals (LGND) Income from Non-Controlling Interests (2011 - 2023)
Ligand Pharmaceuticals (LGND) reported Income from Non-Controlling Interests of $49000.0 for Q1 2023, up 142.98% on a YoY basis from $20166.1 in Q1 2022, and up 240.0% sequentially from -$35000.0 in Q2 2022.
Ligand Pharmaceuticals (LGND) Income from Non-Controlling Interests (2011 - 2023) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 6 years of Income from Non-Controlling Interests data on file, last reported at $49000.0 in Q1 2023.
- For the quarter ending Q1 2023, Income from Non-Controlling Interests rose 142.98% year-over-year to $49000.0; the trailing twelve-month figure through Mar 2023 stood at -$105000.0 (up 39.66% YoY), and the FY2015 full-year result was $2.4 million, up 310.25% from the prior year.
- Income from Non-Controlling Interests advanced to $49000.0 in Q1 2023, from -$35000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $49000.0 in Q1 2023 to a low of -$114000.0 in Q1 2022.
- A 3-year average of -$32000.0 and a median of -$35000.0 in 2022 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests plunged 600.0% in 2022 and surged 142.98% in 2023, its largest moves.
- Tracing LGND's Income from Non-Controlling Interests over 3 years: stood at -$5000.0 in 2021, then sank by 600.0% to -$35000.0 in 2022, then jumped by 240.0% to $49000.0 in 2023.
- Business Quant data shows LGND's Income from Non-Controlling Interests at $49000.0 in Q1 2023, -$35000.0 in Q2 2022, and -$114000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.97 Bn | 466.18 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.05 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.42 Bn | 959.66 Mn | - |
| 10 | Ligand Pharmaceuticals | 5.83 Bn | 5.05 Bn | 48.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 49,000.00 |
| Jun 30, 2022 | -35,000.00 |
| Mar 31, 2022 | -114,000.00 |
| Jun 30, 2021 | -5,000.00 |
| Mar 31, 2021 | -55,000.00 |
| Jun 30, 2015 | -1.54 Mn |
| Mar 31, 2015 | -843,000.00 |
| Dec 31, 2014 | -325,000.00 |
| Sep 30, 2014 | -503,000.00 |
| Jun 30, 2014 | -304,000.00 |
| Jun 30, 2011 | -5,000.00 |